Top Markets
Coin of the day
AzurRx BioPharma, Inc. AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc.

AZRX
Peringkat dalam Saham #35193
AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12... AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12 full-time individuals, focuses on the discovery and advancement of non-systemic biological treatments for various gastrointestinal conditions. Its current developmental portfolio comprises two therapeutic protein assets: MS1819 and AZX1101. MS1819 is an acid-stable lipase enzyme (LIP2), originating from Yarrowia lipolytica, which AzurRx is genetically engineering to address exocrine pancreatic insufficiency (EPI). EPI is a debilitating disorder often seen in patients with chronic pancreatitis (CP) and cystic fibrosis (CF). The second promising compound, AZX1101, is a recombinant beta-lactamase combination sourced from bacteria. This asset is being engineered with a dual aim: to avert nosocomial infections caused by resistant bacterial strains, especially after intravenous beta-lactam antibiotic administration, and to mitigate antibiotic-associated diarrhea (AAD).
Harga Saham
$3.45
Terakhir disinkronkan: 2021-09-21
Kapitalisasi Pasar
$4.29M
Perubahan (1 hari)
2.07%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan AzurRx BioPharma, Inc. (AZRX)

Kategori

Rasio P/B untuk AzurRx BioPharma, Inc. (AZRX)
Rasio P/B per 2026 TTM: 0
Menurut laporan keuangan dan harga saham terbaru dari AzurRx BioPharma, Inc., rasio P/B saat ini (TTM) adalah 0. Pada akhir 2026, rasio P/B perusahaan adalah 0.
Riwayat rasio P/B untuk AzurRx BioPharma, Inc. dari 2026 hingga 2026
Rasio P/B pada akhir setiap tahun
Tahun Rasio P/B Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Rasio P/B untuk perusahaan sejenis atau pesaing
Perusahaan Rasio P/B Perbedaan Rasio P/B Negara
6.3419 -
US
6.2413 -
NL
- -
CH
- -
KR
3.4612 -
BE